Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)

12 novembre 2026 aggiornato da: University Hospital, Angers

Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children

Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.

This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.

Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.

A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Tipo di studio

Osservativo

Iscrizione (Stimato)

360

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Amiens, Francia, 80054
        • CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
        • Contatto:
        • Investigatore principale:
          • Philippe BUISSON, MD
      • Angers, Francia, 49933
        • CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
        • Contatto:
        • Investigatore principale:
          • francoise SCHMITT, MD
      • Clermont-Ferrand, Francia, 63003
        • CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
        • Contatto:
        • Investigatore principale:
          • Carole EGRON, MD
      • Dijon, Francia, 21000
        • CHU Dijon, Service de chirurgie pédiatrique
        • Contatto:
        • Investigatore principale:
          • Michel FRANCOIS, MD
      • Grenoble, Francia, 38700
        • CHU Grenoble, Service de chirurgie pédiatrique
        • Contatto:
        • Investigatore principale:
          • Pierre-Yves RABATTU, MD
      • Le Kremlin-Bicêtre, Francia, 94275
        • Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
        • Contatto:
        • Investigatore principale:
          • Khadidja KHADIR, MD
      • Lyon, Francia, 69677
        • Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
        • Contatto:
        • Investigatore principale:
          • Nicolas CARON, MD
      • Nantes, Francia, 44093
        • CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
        • Contatto:
        • Investigatore principale:
          • Audrey GUINOT, MD
      • Paris, Francia, 75015
        • Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
        • Contatto:
        • Investigatore principale:
          • Rola ABOU TAAM, MD
      • Strasbourg, Francia, 67098
      • Toulouse, Francia, 31059
        • CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
        • Contatto:
        • Investigatore principale:
          • Aurelie LE MANDAT, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 anni a 10 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione di probabilità

Popolazione di studio

Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).

Descrizione

For thoracoscopy group:

Inclusion Criteria:

  • Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Conversion from thoracoscopy to thoracotomy during the procedure
  • Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
  • For Thoracotomy group*:

Inclusion Criteria :

--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification

  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
  • Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification

For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.

*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).

**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
thoracoscopy group

minimally invasive surgical approach

thoracotomy arm

conventionnal surgical approach

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Lasso di tempo: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022.

Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
to evaluate the importance of restrictive syndrome
Lasso di tempo: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)

The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]).

importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
Looking for other respiratory parameters
Lasso di tempo: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation

Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present

the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Lasso di tempo: until spirometry is completed, within a maximum period of 2 years

The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10).

until spirometry is completed, within a maximum period of 2 years
rate of postoperative complications and any necessary reoperations
Lasso di tempo: up to 2 years after the multidisciplinary consultation

The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries.

up to 2 years after the multidisciplinary consultation
Respiratory-related quality of life during childhood
Lasso di tempo: up to 2 years after the multidisciplinary consultation

It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10).

up to 2 years after the multidisciplinary consultation
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Lasso di tempo: through study completion, within a maximum of 24 months

The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis).

through study completion, within a maximum of 24 months
to assess the mortality rate
Lasso di tempo: through study completion, an average 7 years

The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry).

through study completion, an average 7 years
Looking for lung volumes variations
Lasso di tempo: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Lung volume variations will be measured by dynamic respiratory MRI data

the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

2 dicembre 2026

Completamento primario (Stimato)

2 dicembre 2032

Completamento dello studio (Stimato)

2 dicembre 2032

Date di iscrizione allo studio

Primo inviato

22 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 49RC25_0432

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .